MarginsXMarginsX
Home › Markets › Health Care › SLN

Silence Therapeutics Plc American Depository Share (SLN)

SLN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$19.80
-0.15% on the day
Market cap
$1.2B
Small cap
Revenue · 2025
$559K
-98.7% on 2024
Net income · 2025
-$88.6M
-15851.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1479615/000119312526092591/0001193125-26-092591-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSLN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited Kingdom
IPO yearNot reported by the screener
SEC CIK0001479615
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$559K
Net income-$88.6M
Operating income-$91.1M
Net margin-15851.9%
Operating margin-16292.8%
Revenue growth-98.7%
Cash$11.3M
Total assets$131.4M
P/E (computed)Net income was not positive
P/S (computed)2201.5×

Warning signs

Cash runway
67.3 months
$247.7M cash at September 30, 2026
Share count, 1 year
+31.7%
2025-10-30 to 2026-09-30 · +57.0% over 3 years
Going-concern doubt
No
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"As of September 30, 2026, the Group had cash and cash equivalents of $ 247.7 million. 9 Silence Therapeutics plc Notes to the Condensed Consolidated Financial Statements (Unaudited) - ( Continued ) In accordance with Accounting Standards Codification ("ASC") 205-40, Presentation of financial statements: Going concern, the Group has the responsibility to evaluate whether conditions and/or events raise substantial doub"
10-Q 2026-11-13
Cash and burn$247.7M cash; operating cash flow -$11.0M a quarter.Report 2026-09-30
Shares outstanding62,203,024 (2026-09-30); 47,233,949 a year earlier; 39,615,655 three years earlier.Cover page 2026-09-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the marketLatest 2026-08-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Reading, United KingdomPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$12.4M-$12.8M$247.7MNo debt tags$456K10-Q 2026-11-13
Q2 2026
2026-06-30
$0-$12.3M$1.5M$72.1MNo debt tags$615K10-Q 2026-08-10
Q1 2026
2026-03-31
$422K-$15.0M-$15.6M$5.7MNo debt tags$839K10-Q 2026-05-07
Q4 2025
2025-12-31
$34K-$11.8M-$17.3M$11.3MNo debt tags$559K10-K 2026-03-05
Q3 2025
2025-09-30
$159K-$21.0M-$10.9M$82.0MNo debt tags$25.8M10-Q 2026-11-13
Q2 2025
2025-06-30
$224K-$27.4M-$21.8M$41.7MNo debt tags$27.2M10-Q 2026-08-10
Q1 2025
2025-03-31
$142K-$28.5M-$12.3M$64.9MNo debt tags$27.7M10-Q 2026-05-07
Q4 2024
2024-12-31
$25.3M$12.3M-$27.5M$121.3MNo debt tags$43.3M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-12
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-11-12

Source: SEC EDGAR submissions feed, 280 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.5%
1 month+123.6%
3 months+41.9%
Year to date+226.2%
1 year+186.6%
From 52-week high0.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AAPGAscentage Pharma Group International American Depository Shares$13.29-9.10%$1.2B
AMPHAmphastar Pharmaceuticals Inc.$29.17-0.68%$1.2B
NKTRNektar Therapeutics$36.44-2.23%$1.2B
OMEROmeros Corporation$16.68-4.63%$1.2B
OPKOPKO Health Inc.$1.62-3.57%$1.2B
KARDKardigan Inc.$12.85-7.02%$1.2B
MNKDMannKind Corporation$3.96-4.24%$1.3B
GHRSGH Research PLC$18.75-1.83%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier